Pipeline

A robust pipeline to treat the most resistant cancers and neurological diseases

Hard to treat cancers and neurodegenerative diseases demand a diverse arsenal of novel therapeutic approaches.

From monoclonal and bispecific antibodies, to antibody drug conjugates, discover what we have in development.

Fully-owned clinical assets

PD-1/VEGF

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Worldwide Rights

AI-081

Solid tumors

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

OncoC4 Logo

SIGLEC10

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Worldwide Rights

ONC-841

Solid tumors

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

OncoC4 Logo

ONC-841

Alzheimer’s disease

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

OncoC4 Logo

Fully-owned pre-clinical assets

CD24

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Worldwide Rights

ONC-783

Hematologic malignancies

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

OncoC4 Logo

ONC-784

Solid tumors

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

OncoC4 Logo

Late-Stage Clinical Asset in Partnership with BioNTech

CTLA-4

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Worldwide Rights

Gotistobart
(ONC-392)

2L IO-resistant sq NSCLC

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

BioNTech

Gotistobart
(ONC-392)*

Advanced solid tumors

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

  ±pembrolizumab*
BioNTech

Gotistobart
(ONC-392)

mCRPC

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

  +Pluvicto
BioNTech

*In partnership with

MERCK

Clinical trials recruiting now

We are currently recruiting patients for 4 clinical trials in a range of indications.

If you or someone you care about is battling cancer, we welcome you to learn more and get in touch.

BIPAVE-001
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Indications: metastatic disease or locally advanced solid tumors

PRESERVE-004
A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumab

Indications: Platinum-resistant ovarian cancer

PRESERVE-001
A Phase 1 open-label study of gotistobart as a monotherapy and in combination with Pembrolizumab

Indications: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cance, Ovarian Cance, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction adenocarcinoma, Cervical Cancer, AAdenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma

PRESERVE-006
A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetan

Indications: Metastatic Castration-resistant Prostate Cancer

PRESERVE-003
A Phase 3 study of gotistobart versus docetaxel

Indications: Non-Small Cell Lung Cancers that Progressed on PD-1/PD-l1 Inhibitors

ONC-841-002
Safety, Pharmacokinetics (PK) and Efficacy of ONC-841 in Advanced Solid Tumors NCT06352359

Indications: Advanced or metastatic cancers

Clinical trials recruiting soon

For further inquiries about our clinical trials, don’t hesitate to reach out.

Scroll to Top